Millennium Management’s TG Therapeutics TGTX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.27M Buy
+38,300
New +$1.14M ﹤0.01% 4208
2025
Q2
Sell
-10,000
Closed -$394K 6323
2025
Q1
$394K Buy
+10,000
New +$336K ﹤0.01% 4945
2024
Q1
Sell
-181,500
Closed -$3.1M 6652
2023
Q4
$3.1M Buy
+181,500
New +$2.11M ﹤0.01% 3214
2023
Q3
Sell
-101,400
Closed -$2.52M 6561
2023
Q2
$2.52M Sell
101,400
-103,000
-50% -$2.66M ﹤0.01% 3276
2023
Q1
$3.07M Sell
204,400
-46,900
-19% -$712K ﹤0.01% 3028
2022
Q4
$2.97M Buy
251,300
+51,300
+26% +$372K ﹤0.01% 3222
2022
Q3
$1.18M Buy
200,000
+27,400
+16% +$180K ﹤0.01% 4193
2022
Q2
$734K Sell
172,600
-127,400
-42% -$795K ﹤0.01% 4653
2022
Q1
$2.85M Buy
300,000
+217,300
+263% +$2.51M ﹤0.01% 3543
2021
Q4
$1.57M Buy
82,700
+42,700
+107% +$1.11M ﹤0.01% 3988
2021
Q3
$1.33M Buy
+40,000
New +$1.24M ﹤0.01% 4367
2020
Q2
Sell
-100,000
Closed -$984K 4594
2020
Q1
$984K Sell
100,000
-350,000
-78% -$4.42M ﹤0.01% 2477
2019
Q4
$5M Buy
+450,000
New +$3.42M 0.01% 1942
2019
Q2
Sell
-1,025,100
Closed -$8.24M 4450
2019
Q1
$8.24M Buy
+1,025,100
New +$5.54M 0.01% 1404

Other funds holding TGTX

Millennium Management's TGTX Position: Q1 2026 in Review

Millennium Management reduced its TG Therapeutics (TGTX) stake by 82% in Q1 2026, selling an estimated $16.5M and leaving 122,587 shares worth $4.07M. The position accounts for ﹤0.01% of the portfolio, ranked #3176.

Millennium Management first reported a position in TGTX in Q3 2013 and has held it in 43 quarters since. The position peaked at $73.3M in Q4 2022. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Millennium Management held 122,587 shares of TG Therapeutics worth $4.07M as of Q1 2026.
  • Millennium Management sold 553,323 TG Therapeutics shares in Q1 2026, an estimated $16.5M.
  • TG Therapeutics made up ﹤0.01% of Millennium Management's portfolio in Q1 2026, its #3176 holding.
  • Millennium Management first reported a position in TG Therapeutics in Q3 2013 and has held it in 43 quarters since.
  • Millennium Management's TG Therapeutics position peaked at $73.3M in Q4 2022.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.